Avalglucosidase alfa reaches its first important regulatory milestone
AGSD-UK working with NICE towards approval for new treatment for Pompe disease.
Pompe Support Team’s Medical Overview leaflet is now being used in Australia.
Audentes is now enrolling patients with late-onset Pompe disease in the Phase 1/2 clinical trial.
New born screening has long been championed by AGSD-UK. Now you have an opportunity to support a larger national campaign.
A trial of a new treatment for GSD2 has been halted. VAL-1221 was delivered intravenously in late-onset Pompe patients.